Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 25.63
IHE's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 25.63 )
Ranked among companies with meaningful P/E(ttm) only.
IHE' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 25.63
0
30.97
PE(NRI) 25.63
IHE's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 25.63 )
Ranked among companies with meaningful PE(NRI) only.
IHE' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 25.63
0
30.97
P/B 2.64
IHE's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 2.64 )
Ranked among companies with meaningful P/B only.
IHE' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.23
Current: 2.64
0
3.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.01
IHE's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 1.01 )
Ranked among companies with meaningful Dividend Yield only.
IHE' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 1.01
0
1.1
Yield on cost (5-Year) 1.01
IHE's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 1.01 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IHE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 1.01
0
1.1

More Statistics

Short Percentage of Float0.00%
52-Week Range $129.41 - 163.91
Shares Outstanding (Mil)4,800,000.00
» More Articles for IHE

Headlines

Articles On GuruFocus.com
2017 GuruFocus Conference Early Bird Registration Will End on December 15 Dec 06 2016 
Agilent Technologies Raises Dividend 15% Dec 06 2016 
Rising Rates Meet Nesting Urges Dec 06 2016 
Can Zest Fresh Revolutionize an Industry? Dec 06 2016 
Microsoft’s Downside Dec 06 2016 
24 Questions With Value Investor Jacob Taylor of the UC Davis Graduate School of Management Dec 06 2016 
Barnes & Noble Education Reports Sales Slump Dec 06 2016 
Nihon Kagaku Sangyo Looks Undervalued Dec 06 2016 
Why Palo Alto Networks Is the Best Cybersecurity Play Dec 06 2016 
AbbVie, Johns Hopkins Unite for Cancer Research Dec 06 2016 

More From Other Websites
Two Nano-Cap Pharma Stocks To Watch Right Now Dec 02 2016
Pfizer Divests Hospira’s Infusion System Business to ICU Medical Nov 29 2016
Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios Nov 17 2016
Analyzing Future Estimates for Johnson & Johnson Oct 25 2016
Pfizer’s Divestment of Hospira Infusion Systems Oct 14 2016
Medicare Negotiations Would Lead to Huge Cost Savings Oct 03 2016
Analyzing Donald Trump’s Free-Market Healthcare Sep 30 2016
How Does Hillary Clinton Plan to Tame Drug Prices? Sep 30 2016
Generic Drugs Are Crucial in Cost Savings and Accessibility Sep 30 2016
Getting Into The Drug Business: From NDAs To PDUFA Dates Sep 27 2016
The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals... Sep 12 2016
Will a Clinton Presidency Spell Doom for Pharma ETFs? Sep 09 2016
Why Pfizer’s Vaccines Business Is Declining Sep 01 2016
Will Xtandi Fuel Pfizer’s Top-Line Growth? Aug 31 2016
Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns Aug 31 2016
Analyzing Johnson & Johnson’s Business Segments Aug 30 2016
Pfizer’s Products with Decreasing Revenues Aug 11 2016
Pharma ETFs Soaring on Solid Q2 Earnings Aug 03 2016
Trending on ETFdb.com: Emerging Markets and Dividend Kings Garner Interest Jun 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK